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Summary
Caspases are a group of proteolytic enzymes involved in the co-ordination
of cellular processes, including cellular homeostasis, inflammation and
apoptosis. Altered activity of caspases, particularly caspase-1, has been
implicated in the development of intestinal diseases, such as inflammatory
bowel disease (IBD) and colorectal cancer (CRC). However, the
involvement of two related inflammatory caspase members, caspases-4
and -5, during intestinal homeostasis and disease has not yet been
established. This study demonstrates that caspases-4 and -5 are involved
in IBD-associated intestinal inflammation. Furthermore, we found a clear
correlation between stromal caspase-4 and -5 expression levels,
inflammation and disease activity in ulcerative colitis patients.
Deregulated intestinal inflammation in IBD patients is associated with an
increased risk of developing CRC. We found robust expression of
caspases-4 and -5 within intestinal epithelial cells, exclusively within
neoplastic tissue, of colorectal tumours. An examination of adjacent
normal, inflamed and tumour tissue from patients with colitis-associated
CRC confirmed that stromal expression of caspases-4 and -5 is increased
in inflamed and dysplastic tissue, while epithelial expression is restricted
to neoplastic tissue. In addition to identifying caspases-4 and -5 as
potential targets for limiting intestinal inflammation, this study has
identified epithelial-expressed caspases-4 and -5 as biomarkers with
diagnostic and therapeutic potential in CRC.
Keywords: caspases, colorectal cancer, inflammation, inflammatory bowel
disease
Introduction
Inflammatory bowel disease (IBD) is characterized by
chronic, recurrent inflammation of the gastrointestinal
tract and has two main forms – Crohn’s disease (CD) and
ulcerative colitis (UC). The prevalence of IBD in Western
countries is estimated at one in 1000 inhabitants [1], with
worldwide prevalence increasing during the last 50 years
[2]. Numerous studies have consistently supported the
oncogenic impact of chronic inflammation on colorectal
mucosa; thus, IBD patients have an associated risk of devel-
oping colorectal cancer (CRC), with a cumulative 30-year
risk of UC-associated CRC of close to 20% [3–5]. CRC
represents the second most common incident solid organ
cancer in females (after breast cancer) and males (after
prostate cancer), with an estimated annual incidence in
2008 of 12 million worldwide [6]. The pathogenesis of
CRC is complex and is influenced by genetics, lifestyle and
dietary factors; however, an inflammatory microenviron-
ment is a critical component for CRC progression, regard-
less of the initiation pathway [7,8].
In humans, caspases-1, -4 and -5 constitute the inflam-
matory caspase subfamily with roles in both inflamma-
tion and cell death [9,10] . Excessive production of the
inflammatory cytokines, interleukin (IL)-1b and IL-18,
which are dependent upon inflammasome-mediated cas-
pase-1 activation, is found in inflamed colons of IBD
patients [11,12]. IL-1b expression is also up-regulated
during CRC and has been identified as a key factor in
tumour progression and metastasis [13,14]. Thus, it is
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likely that caspase-1 has a role in driving intestinal
inflammation during IBD and CRC [15]. The roles of
caspases-4 and -5 during inflammation are less well char-
acterized than caspase-1, due to the fact that there is no
direct homologue of caspases-4 or -5 in the mouse. How-
ever, murine caspase-11 is considered to be the functional
orthologue of caspases-4 and -5, which are thought to
have arisen following a gene duplication event [16]. To
date, no physiological substrates of caspases-4 or -5 have
been verified in vivo, although there is a growing body of
evidence to support their proinflammatory involvement
in a non-canonical inflammasome. Caspase-4 has been
implicated in NLRP3 [neuronal apoptosis inhibitory pro-
tein, leucine-rich repeat (LRR) and pyrin (PYD)
domains-containing protein 3] inflammasome activation
in keratinocytes following ultraviolet B (UVB) irradiation
[17], and transgenic mice expressing human caspase-4
display higher endotoxin sensitivity, with bone marrow-
derived macrophages (BMDMs) from these mice produc-
ing mature IL-1b and IL-18 following Toll-like receptors
(TLR)-2 and -4 priming alone [18]. Caspase-5 was iden-
tified originally as a component of the NLRP1 inflamma-
some [19]. However, the majority of studies surrounding
non-canonical inflammasome activation have been car-
ried out in murine systems examining caspase-11 [10].
A number of mutational analysis studies have been
carried out to determine whether or not alterations in
inflammatory caspase genes may be involved in the
development of human cancers [20,21]. These have
revealed that the overall incidence of solid tumour muta-
tions is rare for caspases-1 and -4 and occasional for
caspase-5 [20–22], suggesting that mutations in inflam-
matory caspases are not implicated causally in oncogene-
sis [23]. Our study examines the expression, rather than
the sequence, of inflammatory caspases in tissue from
IBD and CRC patients. The revelation that murine
caspase-11 is involved in regulating IL-1b production
through a non-canonical inflammasome following Gram-
negative bacterial infection [24,25] has led us to investi-
gate whether the functional homologues of caspase-11
and human caspases-4 and -5 [24,26] may be involved
in mediating intestinal inflammation during IBD and
CRC.
Methods
Clinical samples
Belgian IBD patient population
This study was approved by the regional ethics committee
(EC 2000/242), and all participating patients signed
informed consent. In total, 103 biopsies were retrieved
from controls [n = 23; 10 males, 13 females, average age
51 yeras (range = 22–69 years)] and patients with CD
[n = 54; 27 males, 27 females, average age 37 years
(range = 8–72)] or UC [n = 16; eight males, eight
females, average age 38 years (range = 7–61)]. All patients
within this cohort were medication-free or on 5-ASA. In
addition, the majority of patients have been included pre-
viously in a genome-wide scan [27].
Irish UC patient population
This study was approved by the Research and Ethics
committee of St Vincent’s University Hospital. All sub-
jects provided written informed consent. Intestinal biop-
sies were retrieved from 36 patients with a diagnosis of
UC, with prospective Mayo scores of endoscopic activity:
Mayo 0 [inactive, n = 11; three males, eight females,
average age 46 years (range = 19–60 years)], Mayo 1
[minimal, n = 7; six males, one female, average age
41 years (range 34–64 years)], Mayo 2 [mild, n = 8;
eight males, average age 37 years (range = 22–76 years)]
and Mayo 3 [moderate to severe, n = 10; seven males,
three females, average age 40 years (range = 29–
61 years)]. All but four patients in this cohort were
receiving medication, including aminosalicylates, cortico-
steroids, immunomodulators or biological therapy (ada-
limumab or infliximab), according to best clinical
practice for treatment of their disease.
Biopsy explant cultures
Colonic biopsy specimens were obtained from patients
undergoing colonoscopy either for UC or for surveillance
investigation (controls). Four patients were recruited
prior to endoscopy and informed consent was obtained.
At the time of endoscopy, two to four biopsies were
taken from healthy, non-adjacent normal and mild
inflamed tissue, and four to eight biopsies were taken
from severe inflamed tissue. Tissue fragments were
placed directly into ice-cold buffer [phosphate-buffered
saline (PBS) containing 100 U/ml penicillin, 100 mg/ml
streptomycin, 4 mg/ml fungizone, 30 mg/ml gentamicin
(Invitrogen, Carlsbad, CA, USA)] and washed three
times before dividing into equal (5 mm) sections and
transferring into 96-well flat-bottomed plates (one sec-
tion per well). Colon sections were covered with media
[RPMI with penicillin/streptomycin and 20% fetal bovine
serum (FBS) (Invitrogen)] supplemented with caspase
inhibitor Z-YVAD-FMK [Z-Tyr-Val-Ala-Asp(OMe)-fluo-
romethylketone] (R&D Systems, Minneapolis, MN, USA)
or vehicle control [dimethylsulphoxide (DMSO)]. Sam-
ples were incubated at 37 C for 18 h before harvesting
supernatants and assaying for IL-1b and IL-6 production
[eBiosciences/Biolegend (San Diego, CA, USA) enzyme-
linked immunosorbent assay (ELISA) kits], according to
the manufacturer’s guidelines. Colonic biopsies were
homogenized in radioimmunoprecipitation assay (RIPA)
buffer [50 mM Tris, pH 8, 150 mM NaCl, 01% (w/v)
sodium dodecyl sulphide (SDS), 05% (w/v) sodium
deoxycholate and 1% (v/v) NP-40] supplemented with
protease inhibitors (Sigma, St Louis, MO, USA). Ten lg
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protein lysate was analysed by Western blot for expres-
sion of capase-1 (Santa Cruz Biotechnologies, Santa
Cruz, CA, USA), caspase-4 and -5 (MBL) and b-actin
(Sigma).
Irish CRC, IBD-associated CRC and polyp patient
populations
The protocol was approved by the Medical Research
Ethics Committee, Beaumont hospital. Areas of tumour
and adjacent normal tissue from 25 sporadic CRC
patients (see Table 1 for characteristics) were assessed by
immunohistochemistry (IHC) for inflammatory caspases-
1, -4 and -5 expression levels. Explant tissue from a fur-
ther eight patients with IBD-associated CRC [six males,
two females, average age 55 years (range = 36–76)] were
assessed for inflammatory caspase expression in areas of
tumour, inflammation and normal adjacent tissue. Polyp
tissue sections were assessed from five patients presenting
with colon polyps and analysed for inflammatory
caspase-4 expression in areas of low-grade dysplasia
(LGD) and normal adjacent tissue.
RNA isolation and conversion to cDNA
Total RNA was extracted from biopsies using the Qiagen
RNeasy Mini Kit (Qiagen, Valencia, CA, USA), with on-
column DNAse treatment according to the manufacturer’s
instructions. The quality and concentration of RNA were
assessed by subjecting samples to automated gel electro-
phoresis and Experion analysis (Bio-Rad, Hercules, CA,
USA). Samples with a 28S/18S ratio between 16 and 18
and a minimum RNA quality index of 7 were included in
the analysis. The WT-OvationTM system from NuGEN
(NuGEN Technologies Inc., San Carlo, CA, USA) was
used to prepare and amplify cDNA, starting from 50 ng
of total RNA, according to the manufacturer’s
instructions.
Quantitative polymerase chain reaction (qPCR)
The real-time PCR primer and probe database (RTpri-
merDB) was used for primer design and in-silico primer
evaluation [absence of secondary structures, single
Table 1. Characteristics of colorectal cancer (CRC) patients and tumours examined for caspases-1, 4 and -5 expression by immunohistochemistry
(IHC)
Patient
no.
Gender,
female (F),
male (M) Age Location Type Stage
1 F 76 Right hemicolectomy Invasive moderately differentiated adenocarcinoma pT3 N2 Mx Duke’s C
2 M 51 Anterior resection Moderately differentiated adenocarcinoma pT3 N1 Mx Duke’s C
3 F 78 Right hemicolectomy Invasive moderately differentiated adenocarcinoma pT3 N0 Mx Duke’s B
4 F 71 Anterior resection Invasive moderately differentiated adenocarcinoma pT4 N2 Mx Duke’s C
5 M 78 Right hemicolectomy Villius adenomata pTis N0 Mx
6 F 41 Anterior resection Focally invasive moderately differentiated adenocarci-
noma, post-neoadjuvant chemotherapy
ypT3 N0 Duke’s B
7 M 61 Sigmoid Invasive moderately differentiated adenocarcinoma pT3 N0 Mx Duke’s B
8 F 78 Right hemicolectomy Invasive moderately differentiated adenocarcinoma pT2 N0 Mx Duke’s A
9 M 64 Rectum Invasive moderately differentiated adenocarcinoma pT2 N2 Mx Duke’s C
10 M 59 Rectum Invasive moderately differentiated adenocarcinoma,
post-neoadjuvant chemotherapy
ypT3 N0 Duke’s B
11 F 50 Right hemicolectomy Ulcerated moderately differentiated adenocarcinoma pT3 N0 Mx
12 M 74 Sigmoid Moderately differentiated adenocarcinoma pT3 N1 Mx Duke’s C
13 F 62 Anterior resection Infiltrating moderately differentiated adenocarcinoma pT1 N0 Duke’s A
14 F 44 Recto-sigmoid Moderately differentiated adenocarcinoma pT2 N0 Mx Duke’s A
15 F 39 Proctocolectomy Synchronous adenocarcinoma in familial adenomatous
polyposis
pT3 N1 Mx Duke’s C
16 M 64 Right hemicolectomy Invasive moderately differentiated mucinous
adenocarcinoma
pT3 N2 Mx Duke’s C
17 F 53 Right hemicolectomy Invasive moderately differentiated adenocarcinoma pT3 N0 Mx Duke’s B
18 F 65 Right hemicolectomy Invasive moderately differentiated adenocarcinoma pT3 N0 M1
19 F 72 Sigmoid Invasive moderately differentiated adenocarcinoma pT1 N0 Mx
20 F 81 Rectum Moderately differentiated adenocarcinoma pT1 N0 Mx
21 F 69 Right hemicolectomy Moderately differentiated adenocarcinoma pT3 N1 Mx Duke’s C
22 F 78 Colon (no area specified) Ulcerated moderately differentiated adenocarcinoma pT4 N0
23 F 81 Colon (no area specified) Well-differentiated adenocarcinoma pT3 N1 Mx Duke’s C
24 M 83 Anterior resection Moderately differentiated adenocarcinoma pT3 N2
25 M 70 Rectosigmoid Poorly differentiated adenocarcinoma, post-
neoadjuvant chemotherapy
ypT3 N0 Mx
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nucleotide polymorphisms (SNPs) and aspecific binding
using the Basic Local Alignment Search Tool (BLAST)].
The conditions of qPCR were set to 60 C annealing tem-
perature, 50 mM Na1 and 3 mM Mg21. To test the PCR-
efficiency of a primer set a dilution series of cDNA or
gDNA was subjected to qPCR analysis, and the efficiency
was calculated as (1021/slope 2 1) 3 100. Primer sets with
efficiencies of 90–110% were used. Primer sequences used
were as follows – CASP1 forward: TGCCTGTTCCTGTG
ATGTGGAGGA, CASP1 reverse: CAGTGGTGGGCATCT
GCGCT; CASP4 forward: ACCGTGGGGAACTGTGGG
TCA, CASP4 reverse: CCAGGACACGTTGTGTGGCGT;
and CASP5 forward: CGCAGACGCCTGGCTCTCAT,
CASP5 reverse: AGCCCAGGCCTTGAAGCAGC. SYBR
green I containing PCR mixtures (8 ll reaction volume;
Roche, Basel, Switzerland) was run on a Lightcycler in
384-well format (LC480; Roche). Cycling conditions were
10 min at 95 C and 40 cycles at 95 C for 15 s and 60
C for 60 s. For each primer set, melting-peak analysis
was performed to verify the specificity of the reaction in
each well. Expression data were normalized using the
median expression of succinate dehydrogenase complex
subunit A (SDHA), hypoxanthine phosphoribosyltransfer-
ase (HPRT) and glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) as reference genes [28]. Data analyses were
performed using the accompanied software and results
were imported to GraphPad Prism (GraphPad Software,
San Diego, CA, USA) for further analysis.
Immunohistochemistry of UC patient biopsies
Immunohistochemistry was performed using formalin-
fixed, paraffin-embedded (FFPE) tissues obtained from
UC patients. A routine three-stage immunoperoxidase
labelling technique incorporating avidin–biotin immuno-
peroxidase complex (Dako, Glostrup, Denmark) was
used. Sections were incubated with primary anti-caspase-
1 (Santa Cruz Biotechnologies Inc.), anti-caspases-4 and -
5 (Medical and Biological Laboratories (MBL), Woburn,
MA, USA) antibodies for 1 h. Sections were also incu-
bated with an appropriate isotype-matched mouse/rabbit
monoclonal antibody as a negative control. Diaminoben-
zadine tetrahydrochloride (DAB; Sigma) was used to visu-
alize staining. Images were captured using the Olympus
DP50 light microscope and AnalySIS software (Soft Imag-
ing System Corporation, Lakewood, CO, USA). Caspase
expression was assessed by two blinded reviewers using a
validated semiquantitative scoring method. All IHC-
stained cells were assessed by a combined score of inten-
sity and percentage of nuclear and cytoplasmic staining.
Staining intensity was graded using a scale of 0–3, where
0 = negative, 1 = weak, 2 = moderate and 3 = strong.
Percentage positivity was graded using a scale of 0–4,
where 0 = no stained cells, 1 = 1–25% stained cells,
2 = 25–50% stained cells, 3 =50–75% stained cells and
4 = 75–100% stained cells.
CRC immunohistochemical analysis
Inflammatory caspase IHC analysis was carried out on a
Bond-III immunostainer from Leica Biosystems (Newcas-
tle upon Tyne, UK). The Bond-III system dewaxed slides
before pretreatment with Bond Epitope Retrieval Solution
I. Primary antibodies – anti-Casp-4 (MBL); anti-Casp-5
(MBL) and anti-Casp-1 (Santa Cruz Biotechnologies
Inc. – were diluted in Bond primary antibody diluent.
Detection and visualization of stained cells was achieved
using the Bond Polymer Refine Detection Kit, using DAB
as the chromagen. Tissues were counterstained with hae-
matoxylin and coverslipped. Appropriate negative controls
(omission of primary antibodies) were used in all assays.
Statistical analysis
Values are expressed as the median and range or
mean 6 standard error of the mean (s.e.m.). The soft-
ware package GraphPad Prism, version 5 (GraphPad Soft-
ware) was used to perform statistical analysis. Differences
in parameters between two groups were performed using
the non-parametric Kruskal–Wallis test (with Dunn’s
post-hoc comparison to control) for qPCR analysis and
unpaired Mann–Whitney U-tests for IHC expression
data. Correlation analysis was undertaken by calculating
the Spearman’s correlation coefficient. P-values of less
than 005 were considered statistically significant.
Results
A study was designed to examine the extent of inflamma-
tory caspase expression in IBD patient intestinal biopsies.
We used real-time PCR to amplify and quantify CASP1,
CASP4 and CASP5 from cDNA prepared from 103 biop-
sies of 53 CD patients, 26 UC patients and 24 healthy
patients. UC/CD healthy or inflamed tissue was obtained
from UC/CD patients with and without endoscopic evi-
dence of inflammation and control tissue was obtained
from endoscopically normal biopsies from non-IBD con-
trol individuals. Caspase-1 expression was elevated signifi-
cantly in colonic tissue samples from inflamed UC/CD
patients (Fig. 1a). Caspases-4 and -5 expression was also
elevated significantly in inflamed colonic tissue, suggest-
ing that, in addition to caspase-1, caspases-4 and -5 may
also have a role during intestinal inflammation (Fig.
1c,e). The data shown in Fig. 1c,d revealed that caspase-4
expression is higher in non-inflamed tissue from IBD
patients (in both ileum and colon), suggesting that it
may be an early marker of IBD. In contrast, both
caspases-1 and -5 expression was significantly higher in
inflamed colonic, not ileal, tissue (Fig. 1a,b,e,f), suggest-
ing their involvement with colitis, rather than ileitis.
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Taken together, these data support the hypothesis that
inflammatory caspases-4 and -5 have an important role
in intestinal inflammation observed during IBD.
To confirm this hypothesis, we examined the relation-
ship between inflammatory caspase expression and both
inflammation and disease activity in UC patients. Disease
activity (Mayo) scores were assigned prospectively to IBD
patients by the physician at the time of endoscopy, and
biopsies from 36 UC patients with Mayo scores ranging
from 0 to 3 (i.e. normal/inactive disease to severe disease)
were coded and sectioned for histological assessment, to
assign an inflammatory score, and immunohistochemical
(IHC) assessment, to stain for caspases-1, -4 and -5
expression. The data demonstrate a strong correlation
(rs = 0636, P < 00001) between the clinical Mayo scores
and the histological inflammation scores (Supporting
information, Fig. S1), confirming the validity of both
scoring systems. Although caspase-1 is expressed at low
levels in non-inflamed tissue, it is expressed strongly in
both epithelial cells and infiltrating immune cells of the
lamina propria in inflamed tissue from patients (Fig. 2a).
A comparison of caspase-1 IHC scores revealed a weak
correlation with inflammation and endoscopic Mayo
scores, revealing that caspase-1 appears to be expressed
maximally once inflammation begins and is sustained
during moderate and strong inflammation (Fig. 2b,c). In
contrast to caspase-1, caspases-4 and -5 expression was
restricted to infiltrating immune cells within the lamina
propria (Fig. 2d,g), and neither caspases-4 or -5 were
detectable within epithelial cells of patients with UC,
regardless of the degree of inflammation (Fig. 2d,g).
Expression of caspase-4 in the lamina propria correlated
clearly with the extent of inflammation (rs = 0502,
P < 00003) (Fig. 2e) and Mayo score (rs = 0504,
P < 00002) (Fig. 2f), with maximum caspase-4 expres-
sion present in sections with inflammatory and Mayo
scores from moderate to strong (scores of 2 and 3).
Caspase-5 IHC staining intensity and percentage
Fig. 1. Increased inflammatory caspase gene
expression in inflammatory bowel disease (IBD)
patient biopsies from a Belgian cohort. Relative
expression of (a,b) caspase-1, (c,d) caspase-4 and
(e,f) caspase-5 in biopsy specimens from non-
IBD healthy control (n = 21), active ulcerative
colitis (UC) patients in endoscopically healthy
(n = 10) and inflamed (n = 11) areas, and active
Crohn’s disease (CD) patients in healthy (n = 38)
and inflamed (n = 21) colon and ileum as
quantified by quantitative polymerase chain
reaction (qPCR). Data are normalized to the
median of three stably expressed reference genes
and represent median and range; *P < 005;
**P < 001; ***P < 0001 (Kruskal–Wallis test
with Dunn’s post-hoc comparison to control).
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expression within the lamina propria correlated with
inflammatory scores up to moderate levels (rs = 0422,
P < 0003) (Fig. 2h) and minimal to mild Mayo scores
(rs = 0473, P < 00007) (Fig. 2i). An experienced clinical
histopathologist (K.S.) identified caspases-4 and -5 IHC
positivity in macrophage, neutrophil and lymphocyte
populations within the lamina propria of these UC
patients.
To further address the role of caspases during UC-
mediated intestinal inflammation, biopsy tissue from
healthy or UC patients with varying degrees of inflamma-
tion were incubated ex vivo in the presence or absence of
the caspase-4 inhibitor, YVAD.fmk. Western blotting
revealed elevated caspase-4 expression in UC patients
with severe inflammation (Fig. 3a), and ELISAs from
biopsy culture supernatants showed that caspase inhibi-
tion resulted in reduced levels of IL-1b and IL-6 produc-
tion from the tissue (Fig. 3b,c). Thus, data from this
study reveal a clear involvement for caspase-4 and, to a
lesser extent, caspases-5 and -1 in UC-associated
inflammation.
IBD is a risk factor for the development of colorectal
cancer (CRC). Having demonstrated the involvement of
inflammatory caspases during IBD, we sought to deter-
mine whether their expression was also elevated in CRC.
Colorectal tumour and adjacent normal tissue samples
from CRC patients were stained for expression of
caspases-1, -4 and -5 by IHC. The CRC samples, regard-
less of the stage of tumour progression or pathway of
genetic instability (Table 1), exhibited similar profiles for
each of the inflammatory caspases. Within the lamina
propria, caspase-1 was expressed in infiltrating immune
cells of tumour tissue and in those of adjacent normal
tissue. Interestingly, there was a more marked increase
in caspases-4 and -5 expression levels within the lamina
propria of tumour tissue compared with adjacent nor-
mal tissue, reflecting the enhanced inflammation occur-
ring within the local tumour microenvironment (Fig.
4a,c). Similar to observations from UC patients,
caspases-4 and -5 staining was identified independently
in macrophage, lymphocyte and plasma cell populations
within the lamina propria of CRC patients by an experi-
Fig. 2. Inflammatory caspases-4 and -5 expression correlates with
clinical disease and inflammation scores in ulcerative colitis (UC)
patient biopsies from an Irish cohort. (a) Representative images of
caspase-1 expression pattern in epithelial cells (top panel) and
stromal cells (bottom panel) from non-inflamed and inflamed UC
biopsy sections. Negative staining was observed for isotype rabbit/
mouse immunoglobulin (Ig)G control (negative control). Original
magnification 320. (d,g) Representative images of caspases-4 and -5
expression patterns in stromal cells of UC biopsy sections. (b,e,h)
Caspases-1, -4 and -5 expression levels correlate with histological
inflammatory scores for UC colonic biopsies. Inflammation score
was graded on a scale of 0–3 (with (0) indicating no activity, (1)
mild activity, (2) moderate activity and (3) severe activity. (c,f,i)
Caspase-1, -4 and -5 expression levels versus endoscopic Mayo score.
Immunohistochemistry (IHC) was performed on colon tissue from
11 non-inflamed UC patients and 25 patients with varying degrees
of inflammation. Data represent mean 6 standard error of the mean
(s.e.m.); *P < 005; **P < 001; ***P < 0001 (Mann–Whitney U-
test).
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enced clinical histopathologist (E.W.K.). Inflammatory
caspase expression in epithelial cell layers contrasted
greatly with the profiles observed in the stroma (Fig.
4b,d). Epithelial cell layers exhibited a striking difference
in caspases-4 and -5 expression levels between normal
and neoplastic tissue. Similar to our observations from
UC patient biopsies, no expression of either caspases-4
or -5 could be detected in adjacent normal tissue; how-
ever, high levels of caspase-4 and -5 were present in
tumour epithelial cells (Fig. 4b,d). With the exception of
one sample (patient 20, Table 1), the switch to epithelial
expression of caspases-4 and -5 was evident in all malig-
nant tissues examined. To investigate whether the overall
increase in caspases-4 and -5 expression could be
detected in CRC patient tissue lysates, areas of normal
and tumour tissue were examined by Western blot (Fig.
4e). The results show increased caspase-4 expression in
malignant homogenates from each of the CRC patients
examined, and increased caspase-5 expression was
detected in three of the five tumour homogenates exam-
ined (Fig. 4e). In support of these observations, exami-
nation of a panel of cell lines by Western blotting
revealed that all CRC cell lines exhibited robust
caspases-4 and -5 expression levels (Fig. 4f). These data
suggest that epithelial expression of caspases-4 and -5
may represent biomarkers of colon carcinoma.
Current chemoprevention strategies for IBD patients
include maintenance anti-inflammatory medications to
prevent dysplasia/cancer development, and surveillance
colonoscopy to identify and treat early lesions. However,
dysplastic lesions associated with IBD-CRC are often diffi-
cult to detect and to grade for severity [29]. To deter-
mine at which point in the inflammation–dysplasia–
carcinoma sequence caspases-4 and -5 expression in epi-
thelial cells is up-regulated, a set of UC-associated CRC
patient resections were examined in areas of normal,
inflamed and tumour tissue for inflammatory caspase
expression. Scoring of the lamina propria in tissue from
these patients had similar expression profiles to those
observed previously in UC patients (Fig. 2) and CRC
patients (Fig. 4a,c), with increased expression of caspases-
4 and -5 in both inflamed and tumour tissue, while nor-
mal tissue displayed high levels of caspase-1, making it
less specific to the inflammatory/malignant status of the
tissue (Fig. 5a,c). Strikingly, epithelial expression of
caspases-4 and -5 were still restricted dramatically to neo-
plastic tissue, even within areas of severely inflamed tissue
(Fig. 5b,d). Areas of normal and inflamed tissue from
CRC patient resections all remained completely negative
for epithelial caspases-4 and -5 expression (Fig. 5b,d),
although a marked increase in caspases-4 and -5 positively
stained intraepithelial infiltrating lymphocytes and macro-
phages was observed in areas of inflamed/dysplastic tissue.
In a further attempt to determine the neoplastic stage at
which the switch to epithelial expression of caspases-4
and -5 occurs, normal and dysplastic areas of polyp tissue
(identified by clinical pathologist E.W.K.) were stained
and scored for caspase-4. As observed previously, all areas
of normal mucosa were void of epithelial caspase-4
expression. Four of the five dysplastic polyp tissues exam-
ined were positive for epithelial caspase-4, while one
remained negative (Fig. 5e,f), suggesting that the switch
Fig. 3. Caspase inhibition attenuates
inflammatory cytokine secretion from ulcerative
colitis (UC) patient biopsies. Colonic explants
biopsy cultures from healthy and UC patients
[non-adjacent normal and inflamed tissue (mild
and severe)] were incubated with Z-YVAD.fmk
[Z-YVAD-FMK (Z-Tyr-Val-Ala-Asp(OMe)-
fluoromethylketone)] (10 lM) or vehicle control
[dimethylsulphoxide (DMSO)] for 18 h. (a)
Caspases-1,-4 and-5 expression levels were
detected by Western blotting. Human acute
monocytic leukaemia (THP1) cell lysate was used
as a positive control for caspase expression.
Secreted levels of (b) interleukin (IL)-1b and (c)
IL-6 were measured by enzyme-linked
immunosorbent assay (ELISA) in culture
supernatants from colonic explants. Results are
representative of two independent experiments.
Data represent mean 6 standard error of the
mean (s.e.m.); *P < 005; ***P < 0001.
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to epithelial expression may occur during low-grade dys-
plasia. To investigate this hypothesis further, dysplastic
CRC tissue was identified in three of the CRC patient
resections analysed previously to generate data for Fig. 4.
The three dysplastic areas were identified as being low-
grade (LGD), high-grade (HGD) and a mix of low- and
high-grade (LGD/HGD). Both LGD and HGD were nega-
tive for epithelial caspase-4 expression, while the LGD/
HGD tissue was epithelial-positive (Supporting informa-
tion, Fig. S2), highlighting the difficulty associated with
determining the stage at which epithelial expression of
caspase-4 occurs. Larger patient numbers and mechanistic
analysis, in parallel with other neoplastic events, such as
the epithelial–mesenchymal transition (EMT), will be
required before any real understanding of when, and how,
the switch to epithelial expression of caspases-4 and -5
occurs.
These findings reveal that caspases-4 and -5 are dis-
criminators between inflamed and neoplastic tissue, and
suggests that there may be significant scope for the detec-
tion of epithelial caspases-4 and -5 as determinants of
malignancy within colorectal mucosa. The presence of
caspases-4 and -5 in epithelial cells could be developed as
a complementary marker to histological assessment of
dysplasia within colon tissue when predicting CRC risk in
patients.
Discussion
This study demonstrates that inflammatory caspases are
expressed highly by infiltrating immune cells in areas of
active inflammation in the gastrointestinal tract of IBD
patients. Relative expression levels, particularly of
Fig. 4. Epithelial expression of caspases-4 and -5
is both specific to, and restricted to, neoplastic
colorectal cancer (CRC) tumour tissue.
Representative images of caspases-1, -4 and -5
expression patterns in (a) stromal and (b)
epithelial regions of adjacent normal (NT) and
tumour (TT) CRC patient resection tissue.
Defined areas of TT and NT were IHC scored for
caspases-1, -4, and -5 expression in (c) stromal;
and (d) epithelial layers. Data represent
mean 6 standard error of the mean (s.e.m.);
*P < 005; **P < 001; ***P < 0001 (Mann–
Whitney U-test). Caspase-1 NT (n = 18),
caspase-1 TT (n = 22); caspase-4 NT (n = 18),
caspase-4 TT (n = 23); and caspase-5 NT
(n = 18), caspase-5 TT (n = 24). Scale
bar = 50 lm. (e) Distal to tumour (non-
adjacent) normal (N) and tumour tissue (T)
lysates (20 lg) from CRC patient resections were
probed by Western blot for caspase-1, -4 and -5.
(f) Western blotting for caspase-4 and caspase-5
in lysates (20 lg) from 293T (control), HCT116,
SW480, SW620 and CACO2 cells. b-actin was
used as a loading control. Results are
representative of three independent experiments.
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caspases-4 and -5, correlate very closely with the level of
tissue inflammation and the grade of disease activity in
UC patients, suggesting that their enhanced expression
has a significant role in disease pathogenesis. The obser-
vation showing elevated caspase-4 mRNA levels in healthy
colon tissue from IBD patients (Fig. 1c) was not sup-
ported by IHC scoring of caspase-4 protein levels in UC
patients (Fig. 2e,f); thus, whether basal caspase-4 expres-
sion is elevated in healthy IBD mucosa compared with
that of healthy, disease-free patients has yet to be
clarified.
Similar to observations in IBD patients, we demon-
strate high expression levels of caspases-4 and -5 in the
stromal compartment of colorectal cancer tissue. Strik-
ingly, we found a dramatic switch in the expression pat-
tern of caspases-4 and -5 in epithelial cells, from no
expression in normal or inflamed tissues to strong
expression in neoplastic tissue. Although the mechanistic
details for these observations are still under way, these
findings reveal strong evidence for the involvement of
caspases-4 and -5 during colorectal inflammation and
carcinoma. As such, this study identifies caspases-4 and -
5 as markers of inflammation and the diagnosis of colo-
rectal cancer.
The expression of inflammatory caspases within the
stroma of both IBD patients and CRC patients appears to
be primarily within infiltrating immune cells, with mac-
rophages, neutrophils, lymphocytes and plasma cells all
found to express caspases-4 and -5. A strong correlation
between inflammation score and caspases-4 and -5
expression was observed in UC patient biopsies, which
supports the hypothesis that caspases-4 and -5 contribute
to intestinal inflammation, most probably through activa-
tion of the non-canonical inflammasome, leading to
increased IL-1b and IL-18 production [24,25]. Although
evidence for the importance of caspases-4 and -5-
mediated non-canonical inflammasome activation during
human inflammation is emerging [17,30,31], the major-
ity of studies to date characterizing non-canonical inflam-
masome activation have been carried out in mice. Recent
publications from our laboratory and others have demon-
strated a protective role for the non-canonical inflamma-
some during a murine model of acute colitis [32,33].
Here, we provide evidence of caspases-4 and -5-mediated
Fig. 5. IHC staining of colitis-associated CRC
(CAC) patient resection tissue and polyp tissue
confirms tumour-specific epithelial expression of
caspases-4 and -5. Representative images of
caspases-1, -4 and -5 expression patterns in
normal, inflamed and tumour (a) stromal; and (b)
epithelial tissue from CAC patient biopsies.
Defined areas of: normal (N) (n = 6); inflamed (I)
(n = 7); and tumour (T) (n = 8) tissue from CAC
patient biopsies were immunohistochemistry
(IHC) scored for caspases-1, -4 and -5 expression
in (c) stromal; and (d) epithelial regions. (e)
Representative images of caspase-4 expression in
defined areas of normal (N) and low-grade
dysplastic (LGD) tissue from colon polyp tissue.
(f) Defined areas of N and LGD from colon polyp
tissues (n = 5) were IHC-scored for stromal and
epithelial caspase-4 expression. Data represent
mean 6 standard error of the mean (s.e.m.);
*P < 005; *P < 001 (Mann–Whitney U-test);
scale bar = 50 lm.
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non-canonical inflammasome activation during intestinal
inflammation in UC patients.
Inflammatory caspases are under transcriptional regula-
tion [24,34]. While caspases-1 and -4 are basally expressed
in monocyte (THP-1) and epithelial carcinoma (HT-29)
cell lines, human caspase-5 and murine caspase-11 expres-
sion is induced in both cell types following stimulation
with bacterial lipopolysaccharide or the pleiotrophic cyto-
kine, interferon (IFN)-g [32,34]. Inflammation is an
essential driving force in the development of epithelial-
originated tumours, and our observation of an increased
infiltration of caspases-4 and -5-expressing immune cells to
the developing tumour site may serve to establish the
tumour inflammatory microenvironment [35]. Instead of
repressing tumour growth, inflammatory cells can promote
tumour growth, particularly during inflammation-
associated cancer [36]. Another significant observation
from this study is the strong expression of caspases-4 and -
5 within the neoplastic epithelium of CRC patients. Within
tumour areas, stromal staining for caspases-4 and -5 was
even stronger than that observed in inflamed tissue, and
epithelial cells became strongly positive for caspases-4 and
-5, suggesting that inflammatory cells may have a role in
inducing the expression of caspases-4 and -5 in colon carci-
nomas. A recent study using co-transplanted endothelial
colony forming and mesenchymal stem cells revealed a role
for caspase-4 expression in neovasculogenesis [37]. Expo-
sure of epithelial cells, or their precursor intestinal stem
cells, to proinflammatory cytokines can induce cancer stem
cell (CSC) markers and cause tumour formation in vivo
[38]. This may represent a plausible mechanism for the
switch to caspases-4 and -5 expression in neoplastic epithe-
lial cells. Alternatively, there may be different, unrelated
mechanisms responsible for caspases-4 and -5 expression
in inflammatory cells and epithelial cells, particularly as
expression in neoplastic epithelium is observed in both
IBD and sporadic CRC tissue. The transcriptional regula-
tion of inflammatory caspases in myeloid and non-myeloid
cell types is an area which requires further investigation.
Expression of caspases-4 and -5 within epithelial cells
may have a different role than within infiltrating immune
cells of the stroma. Previous analysis of the role of
nuclear factor-kappa B (NF-jB) in both epithelial and
infiltrating myeloid cells during a murine model of
colitis-associated CRC revealed that activation of this
inflammatory transcription factor in the two different cell
types drives carcinogenesis through distinct mechanisms,
involving stimulation of proinflammatory cytokines by
infiltrating myeloid cells and prevention of intestinal epi-
thelial cell (IEC) death with tumorigenic potential [39].
Caspase-4 has been attributed previously with a role in
lipopolysaccharide (LPS)-mediated NF-jB activation
[40]. Thus, caspases-4 and -5 may be responsible for driv-
ing tumour initiation by preventing the death of IECs
during CRC.
There are no defined clinical features to predict pro-
gression from inflammation to low-grade dysplasia, and
on to advanced neoplasia. Therefore, histological assess-
ment of biopsy tissue and the identification of dysplasia
are relied upon heavily when making decisions regarding
the management of IBD and the associated risk of CRC
development, and when challenged with the decision of
the requirement for colectomy. However, there are a
number of issues associated with this current CRC sur-
veillance system: first, the difficulty in identification of
true dysplasia versus chronic colonic inflammation [41],
which explains why there is a high level of inconsistency
among pathologists regarding the diagnosis of true dys-
plasia/neoplasia [42,43]. Secondly, patients undergoing
regular colonoscopic surveillance can develop CRC with-
out prior dysplasia, and there is no requirement for low-
grade dysplasia to progress to high-grade dysplasia before
malignancy arises [44,45]. Therefore, there is a serious
requirement for identifiers of neoplasia which can be
assessed in parallel with tissue histology for the identifi-
cation of CRC. We present the expression of caspases-4
and -5 within intestinal epithelial cells as highly specific
biomarkers of colorectal carcinoma, regardless of whether
it occurs following IBD or sporadically. The diagnostic
relevance of our findings is for inflammation-associated
cancer, as distinguishing between neoplastic and chroni-
cally inflamed tissue still represents a major challenge for
pathologists. Our findings may be relevant for the diag-
nosis of CRC, as diagnostic tests to assess caspases-4 and
-5 expression levels within IECs may be developed in
light of these observations. Furthermore, our findings
that caspases-4 and -5 contribute to the inflammatory
status in IBD patients reveals these two caspases as
potential targets for dampening intestinal inflammation.
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Fig. S1. Strong correlation (rs = 0636, P < 00001)
between pathological inflammation scores and clinical
Mayo scores in ulcerative colitis (UC) patient biopsies.
Inflammation scores assigned by a pathologist to UC
patient. Biopsies were graphed against Mayo scores
assigned by the physician at time of endoscopy. Data rep-
resent mean 6 standard error of the mean (s.e.m.);
*P < 005; **P < 001; ***P < 0001 (Mann–Whitney–U-
test).
Fig. S2. Caspase-4 immunohistochemistry (IHC) staining
in dysplastic colorectal cancer (CRC) patient-resected tis-
sue. Images (a) and IHC scores (b) from defined areas of
normal, low-grade dysplasia (LGD), high-grade dysplasia
(HGD) and LGD/HGD mix; CRC patient-resected colon
tissue IHC-stained for caspase-4 (n = 1 for each score).
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